Atopic dermatitis (AD) is a chronic inflammatory and pruritic skin disease arising during the first months of life or at maturity.
In this clinical study, we studied the efficacy of a treatment based on daily use of three cosmetic products: a liquid emollient cleanser, an emollient cream for the body, and an emollient facial cream.
COMPLIFE enrolled 60 volunteers divided in 3 groups of twenty each (G1/G2/G3) that included subjects of 6-36 months, 3-14 years old and + 18 years old, with clinical signs of AD.
All the volunteers were enrolled by a pediatrician and a dermatologist and were assigned to active or placebo treatments.
The volunteers were distributed between our laboratories in the north and south of Italy: G1 and G3 studies were conducted in Complife Italia Srl in San Martino Siccomario, Pavia, Italy; while the study on G2 group was conducted in Nutratech (a Complife Italia Company) in Rende, Cosenza Italy.
The calculation of SCORAD is based on the extent of lesions, on the intensity of lesions (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, dryness), and on subjective symptoms scoring (itching and sleep loss) This item was evaluated with the parents’ collaboration for groups 1 and 2.
The erythema index was measured with Mexameter® MX 18 (Courage+Khazaka Electronic, Köln, Germany) which specifically measures hemoglobin content (erythema) in the skin. Measurements were performed on a skin area showing AD signs on the face and body.
R&D MANAGER AND COSMETIC MARKET MANAGER
In Vivo Safety and Efficacy Supervisor
COMPLIFE. COMMITTED TO SCIENCE, COMMITTED TO YOU.